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Since the landmark Institute of Medicine report brought patient safety to the forefront of 
public concern, there has been intense effort to reduc  medication errors in the hospital 
setting. One such method, medication reconciliation during transitions in care, is now 
standard practice. While many studies have explored contributory factors and 
consequences of medication reconciliation errors at hospital admission and hospital 
discharge, the role of therapeutic interchange, or the substitution of a chemically different 
but therapeutically equivalent drug for the one originally prescribed, on patients’ 
medication regimens has not been adequately investigated. In fact, no study has examined 
the extent to which therapeutic interchange is employed in the hospital and the impact it 
has on unintentional medication reconciliation errors. 
 
We analyzed data from a prospective, observational cohort study of patients 65 years or 
older admitted to a tertiary care hospital for acute coronary syndrome, heart failure, or 
pneumonia between May 2009 and April 2010 who were discharged home. We examined 
patients’ medications from six commonly interchanged drug classes (ACE inhibitors, 
ARBs, H2 blockers, inhaled corticosteroids, PPIs, and statins) and measured the 
frequency of therapeutic interchange at hospital admission, the rate of suspected errors 
associated with therapeutic interchange at admission and at discharge, and the role of 
therapeutic interchange on drug changes at discharge. 
 
We analyzed 555 admission medications taken by 303 patients that were within the six 
drug classes of interest. Of these, 244 (44.0%) were therapeutically interchanged during 
hospitalization while the remaining medications were continued or held. We identified 78 
(32.0%) therapeutically interchanged medications with suspected errors made at time of 
interchange. At discharge, a total of 41 (7.4%) of the 555 medications of interest had a 
suspected medication reconciliation error at discharge. 28 of these were medications that 
were therapeutically interchanged at admission, givin  a relative risk of suspected error 
of 2.75 (95% CI 1.45-5.19) compared to medications that were not interchanged. 28 of 
the 244 therapeutically interchanged medications (11.5%), as compared to 8 of the 311 
non-therapeutically interchanged drugs (2.6%), were switched at discharge to a different 
medication within the same drug class as the patient’s original home medication (RR 
4.46, 95% CI 2.07-9.61). 
 
Therapeutic interchange during hospitalization is a common practice associated with a 
significant number of potential errors at admission and at discharge, creating a risk for 
patient misunderstanding and adverse drug events. In light of these findings, methods for 
safely practicing therapeutic interchange should be eveloped to improve patient safety. 
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Transitions in Care  
 
Since the Institute of Medicine’s 1999 landmark report, “To Err is Human: Building a 
Safer Health System” brought patient safety and medical errors to the forefront of public 
concern, much research has focused on quality improvement in the inpatient and 
outpatient health care settings (1). Concurrently, patient safety advocates have 
increasingly identified transitions in care between these settings as an important source of 
medical error (2). Transitional care has been defined as “a set of actions designed to 
ensure the coordination and continuity of health care as patients transfer between 
different locations or different levels of care within the same location” (3). Ideally, 
transitions occur in a coordinated, transparent fashion based on comprehensive plans of 
care. However, due to the often urgent and unpredictable nature of care transfers, the 
medical complexity of patients being transferred, and the necessity of clear, timely, and 
accurate communication, transitions in care are periods of heightened vulnerability for 
patients (4). The increasing specialization of physicians as well as the restriction of their 
practices to specific phases of care (e.g. only hospital-based or ambulatory-based) can 
further fragment care (4). In fact, in only one such care transition, discharge following 
hospitalization, nearly half of patients may suffer rom a medical error or adverse event 
(5). 
Breakdown in care transitions may occur for many different reasons. These include poor 
communication of essential information between healt c re professionals, failure to 
complete follow-up care, too much time between follow-up care, lack of transportation, 
and incomplete preparation and education of the pati nt and/or family. One of the most 
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Medication errors are one of the most common types of rror affecting patient safety and 
broadly include any failure in treatment by medications that leads to real or potential 
harm to the patient (6). Preventable adverse drug events are associated with up to one in 
five healthcare-related injuries or deaths (7). Significantly, nearly half of these errors 
occur during transitions in care (8). Medication errors during these transfers are typically 
due to incomplete or incorrect transmission of information. The process of obtaining an 
accurate patient medication list and transmitting it to the next phase of care is 
complicated by the fact that there is often no consistent location for keeping this 
information, no integration of medication history across settings, and no standardized 
method for collecting the data (8). As such, medication reconciliation, a formal process of 
identifying the most accurate, current patient medication list and correcting unintended 
discrepancies, is a current patient safety focus aimed at reducing medication errors during 
transitions of care. International organizations such as the World Health Organization and 
Institute for Healthcare Improvement have widely endorsed medication reconciliation in 
the past decade, and the accrediting bodies The Joint C mmission and Accreditation 
Canada mandate this process (9). Medication reconciliation is now standard practice 
during hospital admission and discharge as well as at other points of transfer. For the 
purposes of this thesis, the discussion of medication reconciliation will center on 




Medication reconciliation has been consistently shown to reduce errors and adverse drug 
events (ADEs). For example, Pronovost and colleagues employed a medication 
reconciliation tool in the intensive care unit setting of an academic medical center, which 
required nurses to reconcile prehospital, ICU-admission, and ICU-discharge medications. 
They found that prior to implementation, 94% of ICU patients had at least one 
medication error; 24 weeks afterward, none did (7). At another academic center, use of an 
electronic documentation tool led to a reduction in discharge medication errors from 90% 
to 47% on a surgical unit and from 57% to 33% on a medical unit (10). Vira and 
colleagues showed that pharmacist-led reconciliation in a community hospital was able to 
detect and prevent 75% of clinically important errors (11). One systematic review found 
that 7 of 8 studies demonstrated statistically significant decreases in potential ADEs or 
ADEs (12). 
However, while nearly all medication reconciliation interventions show reductions in 
medication discrepancies and adverse drug events, the effect of these studies on health 
care utilization is less clear. Mueller t al. (2012) identified decreases in post-discharge 
health care utilization in only 2 of 8 studies, and the two that showed improvement 
required intensive pharmacy participation during and fter hospitalization (12). Similarly, 
in another systematic review, Kwan et al. (2013) found that medication reconciliation is 
unlikely to affect 30-day readmission rates or emergency department visits unless 
coupled with additional care coordination interventio s (9). Thus, while medication 
reconciliation is able to detect many errors and may avoid ADEs and potential poor 
outcomes, it may not be sufficient to decrease healt  c re utilization. 
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Of note, despite the national implementation of medication reconciliation processes 
around transitions in care, there is no single standardized method of performing 
medication reconciliation, and many different approaches have been shown to be helpful 
in improving accuracy. Hospital-based medication reconciliation practices can occur at 
multiple times and be completed by various healthcare professionals in many formats 
(12). Medication reconciliation typically occurs at admission and discharge but also may 
be performed in the emergency department, during hospitalization, and after discharge. 
Doctors, nurses, pharmacists, technicians, and/or students can perform reconciliation. 
Information gathering comes from sources such as the patient, caregivers, previous or 
outside hospital records, outpatient physician records, outpatient pharmacies, and 
inpatient progress notes and care teams. Many studies have developed paper and 
electronic tools and protocols to assist in medication documentation, and it is unclear 
which of these methods is superior (12).  
Because of the complex nature of hospital-based medication reconciliation, even 
effective medication reconciliation practices are pone to errors. The following is a 
discussion of the types, reasons, and frequency of medication reconciliation errors at 
hospital admission and hospital discharge. 
Medication Reconciliation Errors at Admission 
 
Obtaining an accurate medication history at the tim of hospital admission is an integral 
part of patient assessment. First, a thorough medication reconciliation may uncover the 
reason for hospitalization, such as an adverse drug event or exacerbation of disease due to 
nonadherence to drug therapy (13). Furthermore, errors in acquiring the outpatient 
medication regimen may lead to interrupted or inappro riate drug therapy during 
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hospitalization and possibly after discharge, which may then cause adverse outcomes 
(13). Though the importance of performing a comprehensive medication reconciliation at 
admission is well understood, many barriers exist to obtaining complete and accurate 
information. 
As noted above, transitions in care are often abrupt and unexpected events in which 
patients and healthcare providers may be unprepared fo  the change in level of care. One 
important source of information for gathering medication history is the patient. However, 
patient knowledge of his/her medications at transitions in care is frequently unreliable 
and incomplete. In one study, only half of patients presenting to the emergency 
department were able to give a list of all of their medications, and only 17% brought a 
written list or their prescription bottles with them. Fewer than one fourth of patients were 
aware of the dosages of their medications (14). In another study, even among patients 
asked to keep a written medication list, 56% of patients had information missing 
(medication, dose, and/or frequency) from the list, and 94% of the lists had at least one 
discrepancy with clinical medical records (15). Because healthcare providers cannot rely 
solely on patient accounts of medication use, they must turn to other sources for data 
gathering and verification. 
Other common sources include family and caregivers, primary care providers, outpatient 
pharmacies, and previous hospital records. Collecting this information is time- and labor-
intensive, and even the most thorough review of data c nnot guarantee complete accuracy 
of the patient’s outpatient medication regimen. Instead, the goal of medication 
reconciliation at hospital admission is to obtain the best possible medication history 
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(BPMH) (16). This BPMH list then becomes the gold standard that is used throughout 
hospitalization. 
The difficulties involved in acquiring the outpatient medication regimen and then 
translating them into inpatient medication orders commonly leads to medication errors. In 
fact, errors at admission are among the most common type of hospital-based medication 
errors, accounting for up to 27% of all inpatient prescribing errors (17-19). In one well-
recognized systematic review of studies describing medication reconciliation errors at 
hospital admission, Tam and colleagues summarized that up to 67% of patients 
experience at least one medication reconciliation error at admission, with a range of 10-
67% (17).  
Studies classifying errors made in medication reconciliation at admission consistently 
show that omission of a home medication is the most c mmon type of error, comprising 
approximately half of admission errors (13,17-19). Other errors include commission, or 
the inpatient prescription of a drug that was not being taken prior to admission (13-22% 
of errors), as well as discrepancies in dose and/or frequency of drug (30-42% of errors) 
(17). 
Consequences of Medication Reconciliation Errors at Admission 
 
Fortunately, while admission medication reconciliation errors are very common, most of 
these discrepancies have no potential for patient harm. Analyses of the clinical 
importance of these errors show that between 60-73% of admission discrepancies are 
unlikely to cause adverse events (13,18,20). Still, the remainder of medication 
reconciliation errors at admission either does cause harm or has the potential to cause 
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patient discomfort or clinical deterioration, as judged by the authors of the studies. 
Examples of potential adverse drug events caused by a mission medication reconciliation 
errors include continuation of an NSAID after  gastrointestinal hemorrhage or 
unintentionally prescribing an increased dose of a sulfonylurea during hospitalization 
(13,20). 
The majority of investigations examining the clinical onsequences of medication errors 
at admission are retrospective chart reviews that look for ADEs or potential ADEs that 
may occur during hospitalization. The studies almost never investigate events after 
hospital discharge. Instead, most discussions of post-discharge ADEs or potential ADEs 
focus on medication reconciliation errors made at discharge (see below). There thus may 
be utility in studying the effect of admission medicat on errors on patients after hospital 
discharge. For instance, Gleason and colleagues found that 22% of admission errors had 
the potential to cause harm during hospitalization but estimated that 59% of the 
admission errors could result in a potential ADE if the error was continued beyond 
discharge (20). Furthermore, in another study examining both admission and discharge 
medication reconciliation errors, one third of all unintentional medication discrepancies 
occurred at admission and were carried through discharge, so any potential ADEs 
associated with these inconsistencies could be attributed to the admission medication 
reconciliation process rather than at discharge (18). Thus, clarifying between post-
discharge clinical consequences that originate upon admission versus at discharge may 




Medication Reconciliation Errors at Discharge 
 
The process of medication reconciliation is also essential at hospital discharge and 
involves merging the patient’s best possible medication history obtained at admission 
with medication changes that occurred during the hospitalization. Hospitalization can 
significantly alter a patient’s medication regimen. In response to acute illness, physicians 
may hold or discontinue medications, change dosages nd frequency of drugs, or start 
new formulations. They may also substitute long-acting or oral medications with short-
acting or intravenous drugs, respectively. Furthermore, hospital formularies may 
necessitate the use of drugs different from preadmission medications (therapeutic 
interchange; see below) (21). Then, at discharge, all of these modifications must be 
thoughtfully reconciled to create a new outpatient r gimen that begins as soon as the 
patient leaves the hospital. Temporary inpatient medications must be stopped, outpatient 
medications may be restarted, and formulary substitutions should be switched back to 
home drugs; the new list should also reflect any additions or modifications made for 
clinical reasons (21). The many changes that occur between admission and discharge 
often lead to medication reconciliation errors at discharge. In fact, two studies have 
shown that half of discharge medication reconciliations contain unexplained 
discrepancies, involving up to 16% of all medications prescribed (22,23). Another study 
found a more conservative error rate of 24%, involving 5% of medications examined 
(24). 
As with errors at admission, the most common type of medication reconciliation 
discrepancy at discharge is omission of a drug, which accounts for 30-45% of errors 
(11,25). Other contributors to discharge discrepancies include changes to dosage and/or 
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frequency, duplication of prescriptions, and incomplete prescriptions (11,25). (The 
continuation of therapeutic interchange has been cit d as a potential source of error but 
has not been explicitly addressed; see below.) 
Consequences of Medication Reconciliation Errors at Discharge 
 
Overall, more medication reconciliation errors occur at hospital admission compared to at 
discharge, but more potential adverse drug events rsult with discharge. This reflects the 
differences between hospitalization, which is often brief and highly monitored, and the 
post-discharge outpatient setting, which has much less healthcare provider oversight so 
errors may continue for a prolonged period of time (18). 
Adverse events related to medications are among the most common undesirable 
outcomes post-discharge. Adverse drug events may arise from various factors, including 
patient misunderstanding and inadequate discharge planning, but often can be traced back 
to medication reconciliation errors. Studies estimae that ADEs occur in 11-31% of 
patients within 30 days of hospital discharge (22,26-28). Many of these, up to 60%, are 
preventable or amendable (27,28). 
These post-discharge ADEs can cause significant morbidity and potentially mortality. 
Patients who experience an ADE after discharge not o ly undergo additional symptoms 
or disabilities but also often require additional health care visits and laboratory testing 





The Rise of Therapeutic Interchange 
 
The ever-increasing complexity and costs of various pharmacotherapies is a large 
contributing factor to our nation’s continued rise n healthcare expenditures (29). 
Therapeutic interchange, or the substitution of a chemically different but therapeutically 
equivalent drug for the one originally prescribed, is a widely used option that 
theoretically allows healthcare systems to provide a safe yet cost-effective method to 
control pharmaceutical expenses and pharmacy size without compromising patient care 
(30). Therapeutic interchange is typically employed in the hospital setting in which there 
is an established formulary but also may occur in the ambulatory setting when patients 
are associated with pharmacy benefit programs (31).Hospitals that have implemented 
therapeutic interchange have reported savings ranging from less than $10,000 to greater 
than $1 million annually (32). Studies examining the economic effects of therapeutic 
interchange within individual drug classes in the outpatient environment have also shown 
the potential for significant cost savings among patients and healthcare systems (30,33-
35).  
A survey by Schachtner et al. that aimed to characterize the prevalence of inpatient 
therapeutic interchange identified the eleven most frequently interchanged medication 
classes in 2002: histamine H2-receptor antagonists, proton pump inhibitors, antacids, 
quinolones, potassium supplements, first-, second-, and third-generation cephalosporins, 
hydroxymethylglutaryl CoA (HMG-CoA) reductase inhibitors, insulin, and 
laxatives/stool softeners (32). Over the past three decades, the percentage of hospitals 




Risks and Benefits of Therapeutic Interchange 
 
Because the exchange of one medication for another may affect patient care and 
outcomes, the use of therapeutic interchange has caused significant debate. Critics of 
therapeutic interchange have highlighted several concerning factors related to patient 
care. Interchanged drugs are typically of the same pharmacologic class, but as they are 
chemically different, they may not be clinically equivalent. Differences in 
pharmacokinetics and pharmacodynamics such as absorption, therapeutic effect, and side 
effect profile may lead to a reduction in effectiveness or increase in side effects (31,38). 
The change in medication also opens the door to prescribing errors that may contribute to 
adverse drug events (21). Finally, pharmaceutical companies compete with each other 
and negotiate with hospital systems and pharmacy benefit programs to have their drugs 
included in these formularies, which can greatly affect prescribing practices (39). While 
hospitals may achieve cost-savings for their formularies, the medications used may not be 
cost-effective for patients when they transition to the outpatient setting. Therapeutic 
interchange may also limit patient choice in both the inpatient and outpatient settings. 
In contrast, others argue that therapeutic interchange can be implemented safely while 
enhancing efficiency. Interchanged medications are similar in effect and mechanism of 
action, and their differences are often well-studied and well-known (31). Proponents 
argue that these changes can be made safely as long as physicians are aware of potential 
unintended consequences (31). A number of studies have shown that switching a 
medication to one within the same class leads to equivalent outcomes for patients without 
significant adverse or side effects (30,33,34,40,41). Furthermore, as the number of 
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available drugs continues to rapidly expand, hospitals utilize therapeutic interchange as a 
practical means of maintaining an efficient, high-quality formulary. 
The debate regarding the relation of therapeutic inerchange to patient care outcomes has 
led to mixed conclusions. Studies of clinical consequences of therapeutic interchange 
have been limited to the effect of single classes of medication on small numbers of 
patients rather than the use of therapeutic interchange as a whole. For example, a study 
looking at a policy change restricting the use of pr ton pump inhibitors to one preferred 
drug showed no change in clinical complications or n ncompliance (30). Other reports 
have shown that exchanging statins or angiotensin receptor blockers leads to equivalent 
clinical outcomes or improvement in lab values without significant adverse events 
(33,40). In contrast, therapeutic interchange of prton pump inhibitors at another 
institution correlated with lack of treatment response and increased side effects (42). 
However, while therapeutic interchange may be controversial, its overall economic 
benefit will continue to drive its existence. 
Role of Therapeutic Interchange in Medication Errors 
Despite substantial research on the cost-effectiveness and equivalency of therapeutic 
interchange, the impact of this practice on patients’ medication regimens and medication 
reconciliation errors has not been fully explored. Upon a patient’s admission to a 
hospital, physicians often continue to prescribe the patient’s outpatient medications with 
modifications as necessary, but hospital formularies fr quently necessitate the 
interchange of home medications for others—formulary medications—that the hospital 
carries. These additional changes may increase the opportunity for medication errors. 
During hospitalization, the modifications may increas  risk of drug-drug interactions, 
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side effects, or adverse effects. At discharge, when physicians perform medication 
reconciliation to determine the patient’s new outpatient regimen, either the original or the 
interchanged drug (or both or neither) may be select d, possibly leading to unintended 
medication discrepancies (43). From the patient’s per ective, the changes may cause 
confusion, and the patient may ultimately take both or neither medication after discharge. 
Continuing the interchanged medication upon discharge may allow cost savings for the 
patient with equivalent or better outcomes, or it may lead to increased prescription costs 
and serious adverse drug effects. 
Medication reconciliation errors made at admission, throughout hospitalization, and at 
discharge have been well-investigated (18). However, though therapeutic interchange has 
been implicated as a possible cause of medication reconciliation errors during hospital 
stays (24), its contributory role has not been explicitly defined. Only one recent study by 
Glaholt et al. (2014) has calculated the frequency at which therap utic interchange 
continues after discharge, but these were not further identified as intentional or 
unintentional modifications. Given the pervasiveness of therapeutic interchange in 
hospital settings and the many means in which it may negatively affect the patient, 









Therapeutic interchange occurs frequently at the tim  of hospital admission and 
contributes to prescriber error during hospitalization. The continuation of therapeutic 
interchange upon discharge is uncommon, as patients are typically placed back on their 
prior outpatient medications. However, the switching of medications via therapeutic 
interchange contributes to medication reconciliation discrepancies at discharge. 
Specific Aims 
 
1. To evaluate the frequency and accuracy at which t erapeutic interchange occurs at 
hospital admission within a tertiary level healthcare system 
2. To assess the extent to which therapeutic interchange continues at discharge into the 
outpatient setting 
3. To determine whether therapeutic interchange contributes to medication reconciliation 






We conducted a retrospective chart review of data collected from a previous study. The 
DIagnosing Systemic failures, Complexities and HARm in GEriatric discharges 
(DISCHARGE) study was a prospective, observational cohort study of patients 65 years 
or older admitted to Yale-New Haven Hospital for acute coronary syndrome, heart 
failure, or pneumonia between May 2009 and April 2010 who were subsequently 
discharged to home. Additional eligibility criteria included speaking English or Spanish, 
not being in hospice care, and participating in a telephone interview; caregivers could 
also take part on behalf of patients. Patients were excluded if they appeared delirious or 
failed a mental status exam. The DISCHARGE study included an examination of 
medication reconciliation accuracy and patient understanding of medication changes 
post-discharge (24). The initial study was approved by the Yale Human Investigation 
Committee. 
During the time period of the study, the hospital used a combination of electronic health 
records (Sunrise Clinical Manager 5.8 (Eclipsys Corporation, Atlanta, GA)) and paper 
medical charts. The admitting physician recorded the admission medication list, or the 
medications being taken upon arrival to hospital, in a paper or electronic note. 
Medications prescribed during hospitalization were documented in handwritten or typed 
progress notes, medication orders were entered electronically, and medications dispensed 
were tracked by an electronic medication administration record (MAR). The discharging 
physician used a prescription writer module to create the discharge medication list, which 
automatically populated into the discharge instructions given to the patient. Clinicians 
performed the medication reconciliations; pharmacists did not systematically review the 
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final discharge list, and there was no active electronic medication reconciliation 
technology. 
In the current study, we examined the therapeutic in erchange of six drug classes: proton 
pump inhibitors (PPIs), histamine H2-receptor antagonists (H2 blockers), 
hydroxymethylglutaryl CoA reductase inhibitors (statins), angiotensin-converting 
enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and inhaled 
corticosteroids (ICS). We selected these drug classes based on their frequency of 
therapeutic interchange, frequency of use, potential he lth impact in the event of 
medication error, and large variances in cost within each drug class. The formulary 
medications and their appropriate conversion dosages for the study institution during the 
study period are listed in Table 1. 
For the current study, the patient sample includes patients who were taking at least one 
medication on admission that fell within the six drug classes listed above (referred to 
henceforth as “medications of interest”). Admission and discharge medication lists were 
previously abstracted but this work was repeated to check for accuracy; inpatient 
medication lists were also abstracted. For each patient, we tracked medications of interest 
from admission to hospital stay to discharge. Using the admission medication list as the 
gold standard, we identified any therapeutic interchanges, change in dose or frequency, 
suspension or discontinuation of medication, and addition of new medication that 
occurred between admission and discharge. 
The occurrence of therapeutic interchange was determin d by comparing the admission 
medication list to inpatient lists and the MAR. If a patient was placed on a formulary 
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medication during hospitalization that was different from the home medication, but of the 
same drug class, we considered that medication to be herapeutically interchanged. In 
contrast, a home medication that was held or continued as the same medication 
throughout hospitalization was not therapeutically interchanged. 
Suspected medication errors include any medication discrepancies at admission or 
discharge that did not appear intentional based on review of the medical record. The 
scope of this study does not include the characterization of all medication reconciliation 
errors at admission but rather focuses on suspected rrors related to therapeutic 
interchange. A correct therapeutic interchange requi s that the physician accurately 
converts the home medication—name, dose, and frequency—to the equivalent formulary 
medication’s name, dose, and frequency. Using Table 1, we noted any inconsistencies in 
the therapeutic interchange as suspected medication conversion errors at admission. 
To identify discrepancies in medication reconciliation at discharge, we compared 
discharge medication lists to their corresponding admission medication lists. Any 
differences to the medications of interest between admission and discharge that did not 
appear intentional were classified as suspected medication reconciliation errors at 
discharge. We then examined whether therapeutic interchange at admission was 
associated with these suspected errors at discharge. 
We further characterized the medications of interest by whether they were changed to a 
different drug (within the same drug class) or not at discharge and examined whether 
therapeutic interchange at admission may be associated with these changes at discharge. 
A drug change at discharge indicates that a patient admitted to the hospital on one 
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medication was discharged to home on a different drug. A drug change may be 
intentional, meaning it was clinically indicated or the result of modifications made during 
hospitalization, or unintentional, meaning there was no apparent clinical indication and 
thus was a suspected error. 
The primary outcomes of this study included the percentage of medications of interest 
that were therapeutically interchanged at admission and the frequency of suspected 
conversion errors made during the interchange, as well as the percentage of medications 
in which drug changes occurred at discharge and the rate of suspected medication 
reconciliation errors associated with therapeutic interchange.  
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Table 1: Formulary Conversions for Drug Classes of Interest 
 
Table 1a: Formulary Conversions for ACE Inhibitors 
FOR THE FOLLOWING ORDERS INTERCHANGE USING 
benazepril  enalapril fosinopril moexipril perindopril ramipril trandolapril quinapril captopril lisinopril 
5mg  QD ---- 5mg  QD 3.75mg  QD 4mg  QD 1.25mg  QD 0.5mg  QD 5mg  QD 25mg  QD 5mg  QD 
10mg  QD 5mg  BID 10mg  QD 7.5mg  QD 
8mg  QD 
2.5mg  QD 1mg  QD 10mg  QD 25mg  BID 10mg  QD 
4mg  BID 
20mg  QD 
10mg  BID* 20mg  QD 15mg  QD ---- 5 mg  QD 2mg  QD 
20mg  QD (HTN) 
---- 20mg  QD (HTN) 
10mg  BID 20mg  BID (CHF) 20mg  BID (CHF) 
                  *20mg QD (HTN and CHF) 
40mg  QD 
20mg  BID 40mg  QD 30mg  QD ---- 10mg  QD 4mg  QD 40mg  QD ---- 40mg  QD 
20mg  BID 
80mg  QD 
---- 80mg  QD ---- ---- 20mg  QD ---- 80mg  QD ---- 80mg  QD 
40mg  BID 
QD = daily, BID = twice daily, HTN = hypertension, CHF = congestive heart failure 
 
Table 1b: Formulary Conversions for ARBs 
FOR THE FOLLOWING ORDERS INTERCHANGE USING 
candesartan eprosartan irbesartan olmesartan telmisartan losartan valsartan 
4mg QD 400mg QD 75mg QD 5mg QD ---- 25mg QD 40mg QD 
8mg QD 600mg QD 150mg QD 20mg QD 20mg QD 50mg QD 80mg QD 
16mg QD 




32mg QD 80mg QD 320mg QD 









Table 1c: Formulary Conversions for H2 Blockers 
  FOR THE FOLLOWING ORDERS INTERCHANGE USING 
CRCL (ml/min) cimetidine nizatidine ranitidine famotidine 
<50 
<30 ml/min: 300mg BID 150mg QD 
150mg QD 20mg QD 
<10ml/min: 300mg QD 150mg QOD 
>50 
300mg Q8H 
150mg BID         
300mg QD 
150mg BID 20mg BID 400mg BID 
800mg QD 
CRCL = creatinine clearance, QD = daily, QOD = every other day, BID = twice daily 
 
Table 1d: Formulary Conversions for ICS 
FOR THE FOLLOWING ORDERS INTERCHANGE USING 
budesonide fluticasone beclomethasone mometasone 
90mcg 1 puff BID       
180mcg 1 puff BID 
44mcg 1 puff BID 
40mcg 1 puff BID         
80mcg 1 puff BID 220mcg 1 puff QD 
50mcg 1 puff BID 
100mcg 1 puff BID 
180mcg 2 puffs BID 
110mcg 2 puffs BID 
80mcg 2 puffs BID 220mcg 1 puff BID 
220mcg 1 puff BID 
  110mcg 4 puffs BID   
220mcg 2 puffs BID   220mcg 2 puffs BID   
  250mcg 2 puffs BID   











Table 1e: Formulary Conversions for PPIs 
FOR THE FOLLOWING ORDERS INTERCHANGE USING 
esomeprazole dexlansoprazole lansoprazole omeprazole rabeprazole pantoprazole 
20mg QD 30mg QD 15mg QD 20mg QD 
20mg QD 40mg QD 
40mg QD 60mg QD 30mg QD 40mg QD 
      
20mg BID       
40mg BID    




40mg BID   30mg BID 40mg BID 
60mg QD ---- 60mg QD 60mg QD 
60mg BID   60mg BID 60mg BID 
      100mg QD 
QD = daily, BID = twice daily 
 
Table 1f: Formulary Conversions for Statins 
FOR THE FOLLOWING ORDERS INTERCHANGE USING* 
fluvastatin lovastatin simvastatin atorvastatin rosuvastatin pravastatin 
20mg QD 10mg QD 5mg QD ---- ---- 10mg QD 
40mg QD 20mg QD 10mg QD ---- ---- 20mg QD 
80mg QD 40mg QD 20mg QD 10mg QD ---- 40mg QD 
---- 80mg QD 40mg QD 20mg QD 5mg QD 80mg QD 
---- ---- 80mg QD 40mg QD 10mg QD ---- 




QD = daily. *Pravastatin was on formulary throughout study period (May 2009 – Apr 2010).  
Atorvastatin was on formulary from May 2009 – Oct 2009. Rosuvastatin was on formulary  








A total of 377 patients were enrolled in the DISCHARGE study, collectively taking 2,583 
oral medications on admission. Of these, 303 (80.4%) patients were taking 555 (21.5%) 
medications at admission that fell within the six drug classes of interest and were 
included in this analysis (see Figure 1). The largest class of medications was statins, 
which accounted for 41% of the medications of interest. On average, 49% of these 
admission medications were non-formulary, or not carried by the formulary of the 
hospital to which they were admitted; rates for individual classes ranged from 20% for 
ACE inhibitors to 75% for PPIs (see Table 2). 











Table 2: Medications of Interest Characterized by Drug Class and Formulary Status 
Admission Meds Non-formulary Formulary 
ACE inhibitor 25 (20%) 97 (80%) 
ARB 15 (25%) 44 (75%) 
H2 blocker 14 (56%) 11 (44%) 
ICS 6 (60%) 4 (40%) 
PPI 84 (75%) 28 (25%) 
statin 129 (57%) 98 (43%) 
Total 273 (49%) 282 (51%) 
 
Suspected Medication Conversion Errors at Admission 
 
Of the 555 medications, 244 (44.0%) were therapeutically interchanged to an approved 
formulary drug at admission. This affected 64% (193 of 03) of the study patients who 
had at least one medication of interest interchanged at admission. The remaining 
medications which were not therapeutically interchanged were either continued 
unchanged as the same drug or were held for the duration of the hospital stay (Table 3).  
Table 3: Classification of Medication Modifications During Hospitalization 
Admission Meds TI Unchanged Held 
ACE inhibitor 11% 63% 25% 
ARB 19% 54% 27% 
H2 blocker 36% 48% 16% 
ICS 50% 10% 10% 
PPI 53% 23% 24% 
statin 64% 30% 5% 
Total 44% 40% 16% 
TI = therapeutic interchange, unchanged = admission medication  
given during hospitalization, held = medication notgiven  
throughout hospitalization 
 
Among the therapeutically interchanged drugs, we identified 78 (32.0%) suspected 
medication conversion errors, affecting 77 different patients, which resulted in the patient 
receiving incorrect treatment in hospital (Fig. 1). Most of the suspected conversion errors 
involved statins (79.2%). For example, one patient taking simvastatin 40mg daily prior to 
admission was placed on pravastatin 40mg daily while inpatient instead of the correct 
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interchange of pravastatin 80mg daily. Of the 78 suspected dose conversion errors made 
at admission, the same potential error was carried forward to the discharge medication list 
in 3 (3.8%) instances. 
Suspected Medication Reconciliation Errors at Discharge 
 
We identified potential medication reconciliation errors at discharge involving 41 (7.4%) 
of the 555 medications of interest (Fig 1). 28 of these were medications that had been 
therapeutically interchanged during admission. This corresponds to a suspected error rate 
of 11.5% (28 of 244) among therapeutically interchanged medications compared to 4.2% 
(13 of 311) among unaffected medications; suspected m ication reconciliation errors 
were significantly more likely to occur among medicat ons that had been therapeutically 
interchanged than those that had not been (RR 2.75,95% CI 1.45-5.19).  
The most common form of suspected medication reconciliation error at discharge 
involved unindicated changes to medication type, with or without additional errors in 
dosage or frequency (first two rows in Table 4). Omission of a medication was also 
frequent; other suspected errors included duplication, inadvertent continuation, or 
incorrect dosing changes. 
Drug Changes at Discharge 
 
36 (6.5%) of the 555 medications of interest were changed at discharge to a different 
medication within the same drug class as the patient’s original admission medication (Fig 
1). The regimen change occurred in 28 of the 244 therapeutically interchanged 
medications (11.5%) as compared to 8 of the 311 non-therapeutically interchanged drugs 
(2.6%), indicating a statistically significant difference (relative risk (RR) 4.46, 95% 
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confidence interval (CI) 2.07-9.61). In 39% of total c ses, these drug changes appeared 
intentional as consequences of inpatient management; for example, a patient admitted on 
esomeprazole was switched to a therapeutically equivalent dose of the formulary drug 
pantoprazole, but because of GI symptoms, the frequency of pantoprazole administration 
was increased, and she was discharged on this new regimen. For the majority of drug 
changes, however, the replacement appeared unintended and was classified not only as a 
drug change but also as a suspected medication recociliation error at discharge. 
Table 4: Suspected Medication Reconciliation Errors at Discharge Characterized by Type 
Type of Suspected Error at Discharge TI No TI 
Different medication in same drug class as 
admission medication prescribed, equivalent in 
dose/frequency, without clear indication 
10 2 
Different medication in same drug class as 
admission medication prescribed, not equivalent 
in dose/frequency, without clear indication 
5 3 
Two medications in same drug class prescribed 3 1 
Admission medication discontinued without clear 
indication; no equivalent medication prescribed 
6 4 
Dose of admission medication incorrect 2 2 
Admission medication continued when intended 
to be stopped 
1 0 
Admission medication prescribed when intended 
to change to different medication 
1 1 
Total 28 13 
TI = therapeutic interchange occurred at admission, No TI = therapeutic 








Our study found that, within six commonly used drug classes, close to half of 
medications were therapeutically interchanged at admission, and errors occurred in one-
third of these conversions. Furthermore, therapeutic in erchange led to 2.75 times more 
suspected medication reconciliation errors and 4.5 times as many changes in drug type at 
discharge. Together, these results indicate that therapeutic interchange is a common 
process that affects patients’ medication regimens from admission to beyond discharge, 
and suggest that therapeutic interchange may be a key contributor to medication 
reconciliation errors. 
This study was limited to six classes of medications; however, of all eligible patients 
included in the original DISCHARGE study, 80.4% of patients were taking at least one 
medication in these six classes, making our study highly generalizable. 64% of included 
patients experienced at least one therapeutic interchange during hospitalization, 
suggesting the importance of thorough evaluation of the effects that therapeutic 
interchange has on medication regimens and errors. 
Previous studies characterizing medication errors made at time of hospital admission do 
not include errors related to therapeutic interchange. Typically, such investigations focus 
on discrepancies made between the admission medication list and patients’ actual 
outpatient regimen when constructing the best possible medication history, but do not 
explore therapeutic interchange as the next step of the transition process. Thus, the 
discovery of a 32% suspected error rate in the imple entation of therapeutic interchange 
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is a novel finding. Given the high rate of the possible interchange errors, more attention 
should be placed on addressing this aspect of patient care around the time of admission. 
These suspected conversion errors suggest that therpeutic equivalence was not achieved 
during hospitalization. This creates an opportunity for adverse drug events and 
complications in inpatient care to arise. Potential adverse events may be exacerbated by 
the fact that patients are likely to be unaware of the changes in medication and do not 
have the means to verify their inpatient regimen for d sing accuracy, as illustrated in a 
study which found that 36% of patients subject to PPI therapeutic interchange during 
hospitalization were unaware that a substitution had occurred (44). Prior studies 
demonstrate that 27-40% of admission medication discrepancies have the potential to 
cause harm during hospitalization, and as they do not include the role of therapeutic 
interchange, the potential for harm may be significantly higher (13,18,19).  
Suspected conversion errors at admission may also hve potential for harm beyond 
hospitalization if they are not remedied at discharge. In this study, 3 of the 78 (3.8%) 
suspected conversion errors were continued at discharge such that the patient may have 
continued the incorrect therapeutic interchange at home. This occurred far less frequently 
than the one-third of admission discrepancies observed by Pippins and colleagues, 
although that included all unintentional medication discrepancies rather than only ones 
related to therapeutic interchange (18). 
At the time of discharge, suspected medication reconciliation errors were identified in 
7.4% of medications analyzed, affecting 12.5% of the patients involved. This rate is 
comparable to other studies, although this study was far reaching than most by including 
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errors of omission, duplication, changes in dosage and frequency, inadvertent 
continuations and therapeutic interchange (24). Again, while other types of medication 
errors at discharge have been previously described, discrepancies related to therapeutic 
interchange have thus far not been specifically examined. Suspected errors were almost 
three times more likely to occur in medications that were interchanged during 
hospitalization; many of these suspected errors involved medications that were not 
reverted back to the home regimen, and were likely a direct consequence of therapeutic 
interchange. The potential for error after discharge is high, as patients may take the 
incorrect dosage of a medication, take two medications of the same class, or discontinue 
an essential treatment.  
Furthermore, we found that in 6.5% of cases, a patient’s admission medication changed 
to a different drug of the same class at discharge. Such changes in medication regimen, 
whether clinically indicated or not, affected 13% of patients who underwent at least one 
therapeutic interchange. This coincides with the 2014 findings of Glaholt et al. who 
observed that 15% of adult patients admitted to an academic medical center who 
experienced therapeutic interchange were not restart d on their original outpatient 
therapy. Medication switches were significantly more likely to occur to medications that 
were changed for formulary reasons than for medications that were unchanged or held 
during hospitalization. 
Minimizing changes to drug regimens, especially in vulnerable populations such as the 
elderly in this study, is important in avoiding patient misunderstanding and potential 
adverse drug effects. Alterations are problematic because patients may have a previous 
home supply available but be required to obtain a new prescription for a therapeutically 
29 
 
equivalent drug following discharge. Subsequent confusion may increase the likelihood 
of medication duplication or omission, possibly putting the patient at risk for drug-drug 
interactions, side effects, and adverse reactions. For these reasons, physicians should 
make changes from one medication to another carefully and only when indicated, and be 
aware of potential unintentional consequences. 
Our study shows that therapeutic interchange is a common practice that likely contributes 
to medication errors at admission and discharge. Given this, healthcare providers must 
give appropriate attention to therapeutic interchange during all aspects of hospitalization, 
and physicians must be careful when making medication modifications due to formulary 
restrictions rather than clinical indication. Aside from provider awareness, we may be 
able to reduce errors related to therapeutic interchange by instituting systems-level 
changes to hospitals. For example, just as standardized protocols can improve medication 
reconciliation, the use of formalized tools likely can make therapeutic interchange safer. 
Medication reconciliation protocols should indicate which medications undergo 
therapeutic interchange at admission and include a m ns of ensuring that this 
interchange is reversed at discharge. Formulary conversion charts such as Table 1 should 
be readily accessible to promote accurate changes. Another potential method of 
improvement is to include pharmacists in the medication reconciliation process. In 
comparison to physicians and other providers, pharmacists are especially suited to this 
responsibility because of their training, but they also are extremely familiar with their 
hospital’s formulary, which may specifically reduce th rapeutic interchange errors 
(17,20,45). The use of an active electronic medication reconciliation system that can flag 
therapeutic interchanges may also aid providers (46). Finally, further studies of the use of 
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therapeutic interchange, reasons for associated errors, and potential adverse events during 
and after hospitalization should be performed to better lucidate the impact of therapeutic 
interchange on patient care. 
Limitations 
 
There are several limitations to this study. First, a  a retrospective chart review, the 
admission medication list documented in the patient charts was treated as the gold 
standard although, as discussed above, numerous studies have shown high rates of 
medication reconciliation errors at admission. Furthermore, we could not verify 
intentional changes or suspected errors to regimens at admission or discharge with the 
patients’ actual providers. Third, the study is limited to patients from a single tertiary 
level hospital in an urban area and may not be generalizable to practices at other 
hospitals. Limiting the investigation to six drug classes rather than all medications may 
affect rates of therapeutic interchange and suspected errors. 
Conclusion 
 
Therapeutic interchange is highly prevalent in the hospital setting but markedly elevates 
the risk for potential medication errors during and fter hospitalization. The benefits of 
therapeutic interchange should be carefully weighed against the potential for increased 
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